# Mustang Bio (MBIO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/MBIO
## Company Profile
- Ticker: MBIO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, CAR-T Therapy, Gene Therapy, Oncology
## Stock Data
- Close: 0.56 USD
- Market cap: 5770270.0575 USD
- Last updated: 2026-09-03
## Business Overview
Mustang Bio is a cell and gene therapy company focused on oncology, including CAR-T and other engineered cell approaches. Its story is built around the possibility that targeted cell therapies can create differentiated outcomes in hard-to-treat cancers.
## Why The Stock Is Moving

As of Sep 3, 2026, MBIO closed up 3.13% at $0.5600. No new same-company headline was identified in the current news window.

## Geographic Base

Mustang Bio is headquartered in the United States and listed on NASDAQ, placing it in the small-cap oncology biotech universe. It sits squarely in development-stage cell therapy rather than commercial large-cap pharma.

## Business Model

The company depends on clinical data, manufacturing execution, and access to capital to keep programs moving. Investors usually focus on trial updates, safety and efficacy signals, and whether the platform can survive long enough to reach meaningful commercialization.

## Landscape Position

Mustang Bio occupies a high-volatility cell therapy niche within biotech. Because it is still heavily development-driven, the stock tends to respond sharply to readouts, financing, and strategic partnerships.

## Future Catalysts

- Mustang Bio’s catalysts are its cell-therapy pipeline, especially any update that clarifies whether the CAR-T and gene-therapy assets still have enough momentum. The stock remains highly data-sensitive.

## Recent News
- 2025-07-07 12:30 EST — [Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma](https://biopharmsignal.com/news/MBIO/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-101-il13ra2-targeted-car-t-cells-to-treat-astrocytomas-and-glioblastoma) — Source: Mustang Bio
- 2025-03-05 21:15 EST — [Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement](https://biopharmsignal.com/news/MBIO/mustang-bio-regains-compliance-with-nasdaq-capital-market-requirement) — Source: Mustang Bio
- 2025-02-27 21:05 EST — [Mustang Bio Announces Sale of Fixed Assets and Exit of Facility](https://biopharmsignal.com/news/MBIO/mustang-bio-announces-sale-of-fixed-assets-and-exit-of-facility) — Source: Mustang Bio
- 2025-02-11 21:10 EST — [Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement](https://biopharmsignal.com/news/MBIO/mustang-bio-regains-compliance-with-nasdaq-minimum-bid-price-requirement) — Source: Mustang Bio
- 2025-02-10 13:00 EST — [Mustang Bio Announces Closing of $8 Million Public Offering](https://biopharmsignal.com/news/MBIO/mustang-bio-announces-closing-of-8-million-public-offering) — Source: Mustang Bio